Page last updated: 2024-09-04

ter 286 and Local Neoplasm Recurrence

ter 286 has been researched along with Local Neoplasm Recurrence in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Boulos, L; Brown, GL; Brown, J; Dombroski, JA; Gomez, RF; Henner, WD; Keck, JG; Laxa, B; Lum, RT; Maack, CA; Mascavage, JC; Reiswig, L; Rosen, LS; Schow, SR	1

Reviews

1 review(s) available for ter 286 and Local Neoplasm Recurrence

Article	Year
Current data and ongoing trials in patients with recurrent non-small-cell lung cancer. Clinical lung cancer, 2004, Volume: 5, Issue:6 Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cytotoxins; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Glutamates; Glutathione; Guanine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Pemetrexed; Prodrugs; Prognosis; Quinazolines; Taxoids	2004

Article

Year

Current data and ongoing trials in patients with recurrent non-small-cell lung cancer.

Clinical lung cancer, 2004, Volume: 5, Issue:6

Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cytotoxins; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Glutamates; Glutathione; Guanine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Pemetrexed; Prodrugs; Prognosis; Quinazolines; Taxoids

2004

Trials

1 trial(s) available for ter 286 and Local Neoplasm Recurrence

Article	Year
Phase I study of TLK286 (glutathione S-transferase P1-1 activated glutathione analogue) in advanced refractory solid malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:5 Topics: Adult; Aged; Cytotoxins; Dose-Response Relationship, Drug; Female; Glutathione; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms	2003

Article

Year

Phase I study of TLK286 (glutathione S-transferase P1-1 activated glutathione analogue) in advanced refractory solid malignancies.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:5

Topics: Adult; Aged; Cytotoxins; Dose-Response Relationship, Drug; Female; Glutathione; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms

2003